Related references
Note: Only part of the references are listed.5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells
Sara Ranjbar et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
Searching for new cytotoxic agents based on chromen-4-one and chromane-2,4-dione scaffolds
Alexandra Gaspar et al.
RESEARCH IN PHARMACEUTICAL SCIENCES (2019)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis
S. Ranjbar et al.
MEDCHEMCOMM (2017)
Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study
Omolbanin Shahraki et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent
Denish Viradiya et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter
Scott A. Steiger et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells
Farnaz Shekari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Thieno[2,3-b]pyridines-A new class of multidrug resistance (MDR) modulators
Aivars Krauze et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverters
Ashish Radadiya et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Samrat A. Khedkar et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2014)
New Insight into P-Glycoprotein as a Drug Target
Albert Breier et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines
Omidreza Firuzi et al.
ARCHIVES OF PHARMACAL RESEARCH (2013)
Dihydropyridines: evaluation of their current and future pharmacological applications
Najmeh Edraki et al.
DRUG DISCOVERY TODAY (2009)
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®
Robert W. Robey et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies
Daniele Tomassoni et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2008)
Strategies to Overcome or Circumvent P-Glycoprotein Mediated Multidrug Resistance
Xun Li et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Synthesis, QSAR and calcium channel modulator activity of new hexahydroquinoline derivatives containing nitroimidazole
Ramin Miri et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients
Isa E. L. M. Kuppens et al.
CLINICAL CANCER RESEARCH (2007)
Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist
Ramin Miri et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The functions and structure of ABC transporters: Implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR)
E. Teodori et al.
CURRENT DRUG TARGETS (2006)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Share Paper
